Medtronic Just Announced a Move That Its Shareholders Should Love

Medtronic (MDT) announced it will spin off its diabetes business, which accounts for 8% of revenue and is its fastest-growing segment at 11% year-over-year growth, into a separate publicly traded entity, potentially within 18 months. The move aims to allow both the new diabetes-focused company and the remaining Medtronic business to pursue more focused growth strategies, with the diabetes unit targeting the intensive insulin management market. While MDT's overall stock performance has been underwhelming, the spin-off offers investors a more direct way to invest in the high-growth diabetes care sector.

Analysis

Medtronic (MDT) has announced a significant strategic restructuring involving the spin-off of its diabetes business into a separate, publicly traded entity, a process expected to take approximately 18 months. This diabetes segment, responsible for 8% of Medtronic's total revenue and 4% of its operating profits, is notably the company's fastest-growing division, with reported revenue of $2.8 billion in fiscal 2025, an increase of nearly 11% year-over-year (almost 12% excluding foreign exchange impacts). The rationale behind this separation is to enable both the new diabetes-focused company and the remaining Medtronic business to pursue more tailored strategies; the former targeting growth-oriented investors interested in the intensive insulin management market, exemplified by its MiniMed 780G system, while the latter caters to those seeking slower growth, dividends (currently yielding 3.4%), and stability. Despite this potentially value-unlocking move, Medtronic's stock has underperformed historically, with a 15% decline over the past five years, though it has seen a modest 4% rise year-to-date. The company currently trades at approximately 15 times estimated next year's earnings. The spin-off aims to provide investors with a distinct opportunity to invest in the high-potential diabetes care sector directly.

Key Decisions for Investors

• Investors seeking exposure to Medtronic's diversified medical device operations, including its stable core business and the future high-growth diabetes spin-off, may consider acquiring MDT shares now, benefiting from the current 3.4% dividend yield and the eventual distribution of shares in the new entity.
• Growth-focused investors particularly interested in the diabetes care market should monitor the spin-off timeline and evaluate an investment in the new, independent diabetes company once it is publicly listed, given its strong revenue growth of nearly 12% ex-FX and focused market position.
• Given Medtronic's historical stock underperformance and the article's note that some analysts do not currently rate it as a top pick, investors should weigh the potential benefits of the spin-off against the established track record and current valuation before committing capital, especially if solely interested in the broader Medtronic entity post-separation.